• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Kineta Announces First Participant Dosed in KCP506 Trial for Chronic Pain americanpharmaceuticalreview
    December 17, 2020
    Kineta, through its subsidiary Kineta Chronic Pain LLC, announced the first participant has been successfully dosed in a Phase 1 clinical trial of KCP506, an investigational, first-in-class α9/α10 nicotinic acetylcholine receptor (nAChR) antagonist in ...
  • Kineta Receives Regulatory Approval for Initiation of KCP506 Trial americanpharmaceuticalreview
    August 18, 2020
    Kineta announced the Clinical Trial Application (CTA) approval in the Netherlands for initiation of a first in-human clinical trial of KCP506. KCP506 is a first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the ...

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service